Clinical and medico-social significance of NAFLD through the prism of comorbidity


DOI: https://dx.doi.org/10.18565/therapy.2019.6.76-86

Bakulin I.G., Abatsieva M. P., Skalinskaya M.I., Zhuravleva M.S.

I.I. Mechnikov North-Western State medical University of the Ministry of Healthcare of Russia, St. Petersburg
The article is dedicated to the modern medical, social, clinical and epidemiological aspects of nonalcoholic fatty liver disease (NAFLD), which in the last 20 years has come out on the first place in prevalence among chronic liver diseases in Russia. The most actual problems of comorbid States in NAFLD are considered. The problems of the course of NAFLD with diabetes mellitus 2, chronic kidney disease, inflammatory bowel diseases, gastroesophageal reflux disease, Helicobacter infection, viral liver lesions, diseases of the circulatory system, pathology of the pulmonary system and others are described.
Keywords: diseases of the circulatory system, steatosis, comorbidity, inflammatory bowel disease, steatohepatitis, gastroesophageal reflux disease, chronic obstructive pulmonary disease, diabetes mellitus, chronic kidney disease
Read entire article

Literature


  1. Электронный ресурс: http://www.gks.ru/free_doc/2018/demo/edn05-18.htm

  2. Williams C.D., Stengel J., Asike M.I. et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011; 140: 124–31.

  3. Loomba R., Sanyal A.J. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013; 10: 686–90. doi: 10.1038/nrgastro.2013.171.

  4. Wong R.J. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Wong R.J., Cheung R., Ahmed A. Hepatology. 2014; 59(6): 2188–95.

  5. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. с соавт. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016; 26(2): 24–42.

  6. Оганов Р.Г., Симаненков В.И., Бакулин И.Г. с соавт. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019; 18(1): 5–66. doi: 10.15829/1728-8800-2017-6-5-56.

  7. Бакулин И.Г., Абациева М.П., Ситкин С.И. с соавт. Оценка метаболома сыворотки крови – перспективный метод диагностики неалкогольной жировой болезни печени у мужчин. Вестник СЗГМУ им. И.И. Мечникова. 2018; 10(4): 5–14.

  8. Mantovani A., Targher G. Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Annals of Translational Medicine. 2017; 5(13): 270. doi: 10.21037/atm.2017.04.41.

  9. Ladep N.G., Khan S.A., Crossey M.M. et al. Incidence and mortality of primary liver cancer in England and Wales: changing patterns and ethnic variations. World J Gastroenterol. 2014 Feb 14; 20(6): 1544–53. doi: 10.3748/wjg.v20.i6.1544.

  10. Konfortion J., Coupland V.H., Kocher H.M. et al. Time and deprivation trends in incidence of primary liver cancer subtypes in England. J Eval Clin Pract. 2014 Aug; 20(4): 498–504. doi: 10.1111/jep.12188.

  11. Wu K.T., Kuo P.L., Su S.B. et al. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. J Clin Lipidol. 2016 Mar-Apr; 10(2): 420–25.e1. doi: 10.1016/j.jacl.2015.12.026.

  12. Ballestri S., Nascimbeni F., Romagnoli D. et al. Type 2 diabetes in non-alcoholic fatty liver disease and hepatitis C virus infection-liver: the «musketeer» in the spotlight. Int J Mol Sci. 2016 Mar 9; 17(3): 355.

  13. Pais R., Giral P., Khan J.F. et al. LIDO Study Group. Fatty liver is an independent predictor of early carotid atherosclerosis. J Hepatol. 2016 Jul; 65(1): 95–102.

  14. Mahfood Haddad T., Hamdeh S., Kanmanthareddy A., Alla V.M. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis. Diabetes Metab Syndr. 2017 Nov; 11 Suppl 1: S209–S216. doi: 10.1016/j.dsx.2016.12.033.

  15. Perera N., Indrakumar J., Abeysinghe W.V. et al. Nonalcoholic fatty liver disease increases the mortality from acute coronary syndrome: an observational study from Sri Lanka. BMC Cardiovascular Disorders. 2016; 16: 37. doi: 10.1186/s12872-016-0212-8.

  16. Minhas A.M., Usman M.S., Khan M.S. et al. Link between non-alcoholic fatty liver disease and atrial fibrillation: a systematic review and meta-analysis. Muacevic A, Adler JR, eds. Cureus. 2017; 9(4): e1142. doi: 10.7759/cureus.1142.

  17. Лю К.М. Коморбидное течение гастроэзофагеальной рефлюксной болезни и неалкогольной жировой болезни печени как фактор риска возникновения кардиальной патологии. Пермский медицинский журнал. 2017; 1: 100–06.

  18. Xue J., Xin H., Ren N., Zhou C. et al. Nonalcoholic fatty liver disease increases the risk of gastroesophageal reflux disease: a systematic review and meta-analysis. European journal of clinical investigation. 2019 Jul 24: e13158.

  19. Yang H.J., Chang Y., Park S.K. et al. Nonalcoholic fatty liver disease is associated with increased risk of reflux esophagitis. Digestive diseases and sciences. 2017; 62(12): 3605–13.

  20. Hung W.-C., Wu J.-S, Yang Y.C. et al. Nonalcoholic fatty liver disease vs. obesity on the risk of erosive oesophagitis. European Journal of clinical investigation. 2014; 44: 1143–49.

  21. Wijarnpreecha K., Panjawatanan P., Thongprayoon C. et al. Association between gastroesophageal reflux disease and nonalcoholic fatty liver disease: a meta-analysis. J Gastroenterol. 2017 Nov-Dec; 23(6): 311–17. doi: 10.4103/sjg.SJG_161_17.

  22. Mantovani A., Turino T., Altomari A. et al. Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: an updated meta-analysis. Targher G.Metabolism. 2019 Jul; 96: 56–65. doi: 10.1016/j.metabol.2019.04.012.

  23. Корнеева О.Н., Драпкина О.М., Павлов Ч.С. с соавт. Неалкогольный стеатогепатит при метаболическом синдроме. Гастроэнтерология. Приложение к журналу Consilium Medicum. 2007; 2: 18–21.

  24. Armstrong M.J., Adams L.A., Canbay A., Syn W.K. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014 Mar; 59(3): 1174–97. doi: 10.1002/hep.26717.

  25. Ahn A.L., Choi J.K., Kim M.N. et al. Non-alcoholic fatty liver disease and chronic kidney disease in Koreans aged 50 years or older. Korean J Fam Med. 2013 May; 34(3): 199–205. doi: 10.4082/kjfm.2013.34.3.199.

  26. Musso G., Gambino R., Tabibian J.H. et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014 Jul 22; 11(7): e1001680. doi: 10.1371/journal.pmed.1001680. eCollection 2014 Jul.

  27. Краснер Я.А., Кулыгина Ю.А., Валуйских Е.Ю., Осипенко М.Ф. Частота и особенности неалкогольного стеатогепатоза у пациентов с воспалительными заболеваниями кишечника в Новосибирской области: одноцентровое поперечное одномоментное исследование 245 больных. Альманах клинической медицины. 2018; 46(5): 464–73. https://doi.org/10.18786/2072-0505-2018-46-5-464-473.

  28. Silva J., Brito B.S., Silva I.N.N. et al. Frequency of hepatobiliary manifestations and concomitant liver disease in inflammatory bowel disease patients. Biomed Res Int. 2019 Jan 31; 2019: 7604939. doi: 10.1155/2019/7604939.

  29. Bessissow T., Le N.H., Rollet K. et al. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016; 22(8): 1937–44.

  30. Carr R.M., Patel A., Bownik H. et al. Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients. Dig Dis. Sci. 2017; 62(5): 1354–61. doi: 10.1007/s10620-017-4495-0.

  31. Canbay A., Nobili V., Ratziu V. et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). Journal of Hepatology. 2016; 64(6): 1388–1402.

  32. Glassner K., Malaty H.M., Abraham B.P. Epidemiology and risk factors of nonalcoholic fatty liver disease among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017 Jun; 23(6): 998–1003. doi: 10.1097/MIB.0000000000001085.

  33. Miele L., Valenza V., La Torre G. et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009 Jun; 49(6): 1877–87.

  34. Tilg H., Cani P.D., Mayer E.A. Gut microbiome and liver diseases. Gut. 2016 Dec; 65(12): 2035–44.

  35. Bosch D.E., Yeh M.M. Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease. Hum Pathol. 2017 Nov; 69: 55–62. doi: 10.1016/j.humpath.2017.09.008.

  36. Sartini A., Gitto S., Bianchini M. et al. Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. Cell Death Dis. 2018; 9(2): 87. doi: 10.1038/s41419-017-0124-2/

  37. Adams L.C., Lübbe F., Bressem K. et al. Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: a case-control study. PLoS One. 2018 Nov 14; 13(11): e0206450. doi: 10.1371/journal.pone.0206450. eCollection 2018..

  38. Чижова О.Ю. Клинические аспекты обструктивных нарушений дыхания во сне и ассоциированных с ними состояний. Дис. д-ра мед. наук. Санкт-Петербург, 2006. 252 с.

  39. Platt L., Easterbrook P., Gower E. et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect. Dis. 2016; 16(7): 797–808.

  40. Жданов К.В., Козлов К.В., Сукачев В.С. Гепатит С и неалкогольная жировая болезнь печени у пациентов с ВИЧ-инфекцией. ВИЧинфекция и иммуносупрессии. 2017; 9(1): 36–42.

  41. Stevenson H.L., Utay N.S. Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era. Trop Dis Travel Med Vaccines. 2016 Sep 27; 2: 21. doi: 10.1186/s40794-016-0038-5.

  42. Жданов К.В. Карякин С.С., Козлов К.В. с соавт. Хронический гепатит C и неалкогольная жировая болезнь печени. Основные аспекты патогенеза. Вестник российской военно-медицинской академии. 2018; 1(61): 216–221.

  43. Бакулин И.Г. Актуальные вопросы противовирусной терапии хронических гепатитов В и С. Экспериментальная и клиническая гастроэнтерология. 2010; 5: 3–9.

  44. Абдурахманов Д.Т., Морозов В.Г., Никитин И.Г. с соавт. Безопасность и эффективность телапревира в лечении хронического гепатита С у больных российской популяции, включенных в исследование по программе раннего доступа. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014; 24(1): 39–46.

  45. Жданов К.В., Бакулин И.Г., Гусев Д.А. с соавт. Эффективность и безопасность комбинации рибавирина и пегилированного интерферона альфа-2а у пациентов с хроническим гепатитом C: результаты двух мультицентровых, проспективных, открытых, несравнительных клинических исследований. Журнал инфектологии. 2017; 9(4): 59–68.


About the Autors

Igor G. Bakulin, MD, professor, head of the Department of propedeutics of internal diseases, gastroenterology and nutrition named after S.M. Ryssa of I.I. Mechnikov North-Western State medical University of the Ministry of Healthcare of Russia. Address: 195067, St. Petersburg, 47/24 Piskarevsky Prospect. Tel.: +7 (961) 612-77-12. E-mail: igbakulin@yandex.ru; igor.bakulin@szgmu.ru
Madina P. Abatsieva, graduate student of the Department of propedeutics of internal diseases, gastroenterology and nutrition named after S.M. Ryssa of I.I. Mechnikov North-Western State medical University of the Ministry of Healthcare of Russia. Address: 195067, St. Petersburg, 47/24 Piskarevsky Prospect. Tel.: +7 (911) 840-65-15. E-mail: madina.abacieva@mail.ru; madina.abatcieva@szgmu.ru
Maria I. Skalinskaya, PhD, associate professor of the Department of propedeutics of internal diseases, gastroenterology and nutrition named after S.M. Ryssa of I.I. Mechnikov North-Western State medical University of the Ministry of Healthcare of Russia. Address: 195067, St. Petersburg, 47/24 Piskarevsky Prospect. Tel.: +7 (961) 607-01-85. E-mail: mskalinskaya@yahoo.com; Mariya.Skalinskaya@szgmu.ru
Maria S. Zhuravleva, PhD, assistant of the Department of propedeutics of internal diseases, gastroenterology and nutrition named after S.M. Ryssa of I.I. Mechnikov North-Western State medical University of the Ministry of Healthcare of Russia. Address: 195067, St. Petersburg, 47/24 Piskarevsky Prospect. Tel.: +7 (906) 277-31-32. E-mail: ms_zhuravleva@mail.ru; Mariya.Zhuravleva@szgmu.ru


Similar Articles

Back to Content

Бионика Медиа